Merck
HomeWebinarsDriving the Evolution Towards Intensified Upstream Processing

Driving the Evolution Towards Intensified Upstream Processing



WEBINAR

What are the challenges that come with achieving intensified upstream processing? Join us to learn about how new and innovative single-use and next-generation upstream technologies achieve robust bioprocessing with increasing speed, flexibility, and productivity.

In the current paradigm shift and transformation in biomanufacturing for a facility of the future, various approaches are being taken to realize a true ecosystem of intensified, connected, and continuous processing seamlessly coupled with process analytical technologies (PATs). Intensified upstream processing offers a viable option for improving cell culture productivity enabling many operational benefits like process speed and facility utilization.

This presentation will summarize the current challenge and trends of upstream processing and describe the latest approaches for process intensification powered by PATs and Single-Use technology for closed processing.

In this webinar, you will learn:

  • Consideration for novel intensified upstream processing
  • Various intensification approaches from seed train to production 
  • Ready-to-use, robust, and scalable intensified upstream solutions

Speakers

Takao Ito, Ph.D.

Takao Ito, Ph.D.

Merck

Principal Consultant, Asia Pacific Global BioPharm CoE

Takao Ito is a principal consultant, focused on biopharmaceutical processing, for Merck. He has worked in the area of bioprocess engineering for more than 20 years. He has more than 20 years of experience in the area of bioprocess engineering, working across multiple technologies within bioprocess development, scale-up, and GMP manufacturing. He currently helps the intensified bioprocess grow and evolve innovative technologies for the upstream/downstream applications. Takao Ito holds an M.S. in mechanical engineering and a Ph.D. in chemical engineering.

Sun-ha Song

Sun-ha Song

Merck

Upstream Process Development Scientist

Sun-ha Song is an upstream PD scientist in Merck's technical and scientific solutions group for the APAC (excluding China) region. She has more than 7 years of experience in upstream bioprocess from cell line development to bioreactor engineering for the mAb Industry as well as virus generation and analytical method development for the vaccine industry.

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?